138022-86-3 Usage
Uses
Used in Pharmaceutical Development:
1-Azetidin-3-yl-piperidine is used as a potential drug candidate for various medical applications due to its unique structure and pharmacological properties. Its heterocyclic nature may contribute to the development of new therapeutic agents.
Used in Chemical Synthesis:
In the chemical synthesis industry, 1-Azetidin-3-yl-piperidine is used as a building block or intermediate in the synthesis of more complex molecules, potentially leading to the creation of novel compounds with specific applications.
Used in Medicinal Chemistry Research:
1-Azetidin-3-yl-piperidine serves as a subject of interest in medicinal chemistry research, where its structure and properties are studied to understand its potential interactions with biological targets, which could lead to the discovery of new drugs or therapeutic agents.
Check Digit Verification of cas no
The CAS Registry Mumber 138022-86-3 includes 9 digits separated into 3 groups by hyphens. The first part of the number,starting from the left, has 6 digits, 1,3,8,0,2 and 2 respectively; the second part has 2 digits, 8 and 6 respectively.
Calculate Digit Verification of CAS Registry Number 138022-86:
(8*1)+(7*3)+(6*8)+(5*0)+(4*2)+(3*2)+(2*8)+(1*6)=113
113 % 10 = 3
So 138022-86-3 is a valid CAS Registry Number.
InChI:InChI=1/C8H16N2/c1-2-4-10(5-3-1)8-6-9-7-8/h8-9H,1-7H2
138022-86-3Relevant academic research and scientific papers
Synthesis of new quinolone antibiotics utilizing azetidine derivatives obtained from 1-azabicyclo[1.1.0]butane
Ikee, Yoshifumi,Hashimoto, Kana,Kamino, Mai,Nakashima, Masaaki,Hayashi, Kazuhiko,Sano, Shigeki,Shiro, Motoo,Nagao, Yoshimitsu
, p. 346 - 356 (2008/12/22)
A series of 3-sulfenylazetidine derivatives 5a-f were synthesized via the ring-opening reactions of 1-azabicyclo[ 1.1.0]butane (ABB, 3) with thiols 4a-f in 50-92% yields. Treatment of ABB (3) with aromatic amines 9a-e and dibenzylamine (9f) in the presence of Mg(ClO4)2 afforded the corresponding 3-aminoazetidine derivatives 10a-f in 24-65% yields. N-Benzyl-3-bromoazetidine (13), which was obtained by the reaction of ABB (3) with benzyl bromide, gave 3-aliphatic amino-substituted azetidine derivatives 15a, b. Novel fluoroquinolones 7a-f, 11a-f, 16a, b and 25a-c were obtained by the introduction of these azetidine derivatives into the C7 position of a quinolone nucleus 6 and N1-heterocyclic quinolones 21a-c in 21-83% yields. Some of them exhibited a greater antibacterial activity against methicillin-resistant Staphylococcus aureus (MRSA) in comparison with that of clinically used fluoroquinolone, levofloxacin (LVFX).
